📣 VC round data is live. Check it out!
- Public Comps
- Aroa Biosurgery
Aroa Biosurgery Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aroa Biosurgery and similar public comparables like JETEMA Co., Guerbet, Viromed Medical, Quanterix and more.
Aroa Biosurgery Overview
About Aroa Biosurgery
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Founded
2007
HQ

Employees
251
Website
Financials (LTM)
EV
$151M
Valuation Multiples
Start free trialAroa Biosurgery Financials
Aroa Biosurgery reported last 12-month revenue of $63M and EBITDA of $7M.
In the same LTM period, Aroa Biosurgery generated $54M in gross profit, $7M in EBITDA, and $2M in net income.
Revenue (LTM)
Aroa Biosurgery P&L
In the most recent fiscal year, Aroa Biosurgery reported revenue of $55M and EBITDA of $3M.
Aroa Biosurgery is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of 5%, and net margin of (4%).
Financial data powered by Morningstar, Inc.
Aroa Biosurgery Stock Performance
Aroa Biosurgery has current market cap of $161M, and enterprise value of $151M.
Market Cap Evolution
Aroa Biosurgery's stock price is $0.46.
Aroa Biosurgery share price increased by 3.4% in the last 30 days, and by 28.2% in the last year.
Aroa Biosurgery has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $151M | $161M | 5.4% | 3.4% | -3.4% | 28.2% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAroa Biosurgery Valuation Multiples
Aroa Biosurgery trades at 2.4x EV/Revenue multiple, and 21.5x EV/EBITDA.
EV / Revenue (LTM)
Aroa Biosurgery Financial Valuation Multiples
As of May 7, 2026, Aroa Biosurgery has market cap of $161M and EV of $151M.
Aroa Biosurgery has a P/E ratio of 67.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aroa Biosurgery Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Aroa Biosurgery Margins & Growth Rates
Aroa Biosurgery grew revenue by 12% and EBITDA by 170% in the last fiscal year.
In the most recent fiscal year, Aroa Biosurgery reported gross margin of 86%, EBITDA margin of 5%, and net margin of (4%).
Aroa Biosurgery Margins
Aroa Biosurgery Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Aroa Biosurgery Operational KPIs
Aroa Biosurgery's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Aroa Biosurgery's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aroa Biosurgery's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Aroa Biosurgery Competitors
Aroa Biosurgery competitors include JETEMA Co., Guerbet, Viromed Medical, Quanterix, Hyperfine, Sisram Medical, Neuronetics, EKF Diagnostics, BICO Group and Pro-Dex.
Most Aroa Biosurgery public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.6x | — | 30.7x | — | |||
| 0.5x | 0.6x | 6.0x | 5.1x | |||
| — | 5.4x | (666.9x) | 39.4x | |||
| 0.5x | 0.5x | (0.8x) | (2.0x) | |||
| 9.8x | 8.4x | (3.7x) | (3.9x) | |||
| 0.4x | 0.4x | 2.9x | 3.7x | |||
| 1.4x | 1.4x | (7.6x) | (11.7x) | |||
| 1.9x | 1.9x | 7.8x | 7.8x | |||
This data is available for Pro users. Sign up to see all Aroa Biosurgery competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aroa Biosurgery
| When was Aroa Biosurgery founded? | Aroa Biosurgery was founded in 2007. |
| Where is Aroa Biosurgery headquartered? | Aroa Biosurgery is headquartered in United States. |
| How many employees does Aroa Biosurgery have? | As of today, Aroa Biosurgery has over 251 employees. |
| Is Aroa Biosurgery publicly listed? | Yes, Aroa Biosurgery is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Aroa Biosurgery? | Aroa Biosurgery trades under ARX ticker. |
| When did Aroa Biosurgery go public? | Aroa Biosurgery went public in 2020. |
| Who are competitors of Aroa Biosurgery? | Aroa Biosurgery main competitors include JETEMA Co., Guerbet, Viromed Medical, Quanterix, Hyperfine, Sisram Medical, Neuronetics, EKF Diagnostics, BICO Group, Pro-Dex. |
| What is the current market cap of Aroa Biosurgery? | Aroa Biosurgery's current market cap is $161M. |
| What is the current revenue of Aroa Biosurgery? | Aroa Biosurgery's last 12 months revenue is $63M. |
| What is the current revenue growth of Aroa Biosurgery? | Aroa Biosurgery revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Aroa Biosurgery? | Current revenue multiple of Aroa Biosurgery is 2.4x. |
| Is Aroa Biosurgery profitable? | Yes, Aroa Biosurgery is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aroa Biosurgery? | Aroa Biosurgery's last 12 months EBITDA is $7M. |
| What is Aroa Biosurgery's EBITDA margin? | Aroa Biosurgery's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Aroa Biosurgery? | Current EBITDA multiple of Aroa Biosurgery is 21.5x. |
| What is the current FCF of Aroa Biosurgery? | Aroa Biosurgery's last 12 months FCF is $5M. |
| What is Aroa Biosurgery's FCF margin? | Aroa Biosurgery's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Aroa Biosurgery? | Current FCF multiple of Aroa Biosurgery is 27.8x. |
| How many companies Aroa Biosurgery has acquired to date? | Aroa Biosurgery hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Aroa Biosurgery has invested to date? | Aroa Biosurgery hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Aroa Biosurgery
Lists including Aroa Biosurgery
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.